Daily weight loss pill achieves main goal in late-stage trial Data from an earlier study of the drug in patients without diabetes sent company shares tumbling The Independent UK · Aug 26, 2025
Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes. Benzinga · Aug 26, 2025
Diabetes smartphone test could diagnose condition in under 10 minutes The creators of the world-first app at diagnostics company PocDoc say the test could also save the NHS billions The Independent UK · Aug 22, 2025
UK firms misleading parents with milk teeth autism treatment claims, report finds Charity says it is ‘outrageous’ tooth stem cell procedures are being advertised with claims about ‘treating’ autism The Guardian - UK · Aug 21, 2025
Exclusive: Twin Health, metabolic health startup, raises $53 million Series E at $950 million valuation Twin Health raised a $53 million Series E led by Maj Invest of Denmark, Fortune has exclusively learned. Fortune · Aug 21, 2025
The supplement that could help with weight loss for people with diabetes Turmeric and curcumin may offer modest benefits for weight management in people with prediabetes and type 2 diabetes, a new study found The Independent UK · Aug 20, 2025
Diabetes patients could be offered weight loss jabs sooner in major shake-up The changes will impact millions of people with type 2 diabetes in England in the biggest shake-up of care in a decade The Independent UK · Aug 19, 2025
Type 2 diabetes patients set for major shake-up in care New draft guidance from the National Institute for Health and Care Excellence suggests the NHS should move away from a one-size-fits-all approach. The Independent UK · Aug 19, 2025
Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes. Benzinga · Aug 19, 2025
Continuous glucose monitors: should people who don’t live with diabetes be wearing them? Gwyneth Paltrow and other celebrities and influencers are sporting CGMs, but counting your glucose levels provides little benefit if you don’t have diabetes The Guardian - AU · Aug 19, 2025
Half-off Ozempic? US patients paying in cash can now buy the popular weight-loss drug for less The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes patients The Independent UK · Aug 19, 2025
Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients The previous out-of-pocket price was nearly $1,000. Fortune · Aug 18, 2025
New study finally busts health myth of much-loved tropical fruit Clinical trials replaced breakfast bread with a mango and monitored glycemic responses The Independent UK · Aug 16, 2025
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom. Benzinga · Aug 15, 2025
International Business Times UK · Aug 15, 2025 Mounjaro Is About to Get More Expensive in the UK: Here Are Cheaper Alternatives Available Right Now Mounjaro's UK price will rise by 170% in September, prompting interest in cheaper alternatives like semaglutide for weight loss.
The Guardian - US · Aug 14, 2025 Ozempic didn’t work for me. I was furious – and ashamed Everyone taking the ‘skinny shot’ was losing weight, but my scales didn’t change. My inner dialogue became toxic
The Independent UK · Aug 14, 2025 Breakthrough drug that slows onset of type 1 diabetes set for UK release Teplizumab can allow patients to live “normal lives” without the need for insulin injections
Evening Standard · Aug 14, 2025 Drug that slows onset of type 1 diabetes licensed for use in UK-first The cost-effectiveness of the drug for NHS roll-out will now be assessed by the National Institute for Health and Care Excellence.
Benzinga · Aug 14, 2025 Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen.
LiveScience · Aug 13, 2025 Diabetic man produces his own insulin after gene-edited cell transplant The new proof-of-concept study points a way to curing diabetes without the need for immune-suppressing drugs.
Benzinga · Aug 13, 2025 Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.
The Independent UK · Aug 13, 2025 The lifestyle medicine that could clear menopausal brain fog Lifestyle medicine uses interventions to prevent and manage chronic conditions such as heart disease, diabetes and dementia
The Independent UK · Aug 12, 2025 Study links weight-loss drugs to serious eye conditions and vision loss Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye complications
The Conversation · Aug 11, 2025 Ozempic and other weight-loss drugs linked to rare but serious eye conditions Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world.
MarketBeat · Aug 9, 2025 Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.